Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia

Animesh Pardanani, Terra Reeder, Chin Yang Li, Ayalew Tefferi

Research output: Contribution to journalArticlepeer-review

68 Scopus citations

Abstract

Twenty to thirty-three percent of systemic mast cell disease (SMCD) patients have some degree of peripheral blood and/or bone marrow eosinophilia. While the clonality of SMCD was established by identification of the pathogenic c-kit Asp816 to Val (D816V) mutation in sorted cells of different hematopoietic lineages, this mutation has not previously been demonstrated in eosinophils from SMCD patients. In the current study, we demonstrate the D816V mutation in purified eosinophils from two patients with aggressive, eosinophilia-associated SMCD, thus proving that the eosinophils are clonal and not reactive in nature. The clinical implications of this finding are discussed.

Original languageEnglish (US)
Pages (from-to)883-885
Number of pages3
JournalLeukemia Research
Volume27
Issue number10
DOIs
StatePublished - Oct 1 2003

Keywords

  • Eosinophilia
  • Leukemia
  • Mastocytosis
  • Receptor tyrosine kinase
  • c-kit mutation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia'. Together they form a unique fingerprint.

Cite this